SAS Drug Development Adds Genomic-Analysis Capabilities

Published on: 

Applied Clinical Trials

Applied Clinical Trials, Applied Clinical Trials-06-20-2006, Volume 0, Issue 0

Solution addresses biomarkers, incorporates molecular information

PHILADELPHIA, June 19, 2006-SAS, the leader in business intelligence, today announced new genomic-analysis capabilities for its flagship life sciences offering, SAS® Drug Development. These new capabilities will make it easier for pharmaceutical companies to analyze genetic data and incorporate this analysis into new drug applications.

SAS Drug Development is a powerful data management and analysis solution for pharmaceutical, medical device and biotechnology firms. More than 90 processes for genomic and proteomic-specific molecular analyses-powered by JMP® software-are now incorporated into SAS Drug Development, addressing the areas of:

  • Genetics. For genetic marker data, case-control or pedigree experiments. Useful for characterizing genetic variability and evaluating its association with biological effects, such as disease or adverse events.
  • Microarrays. For gene expression or RNA transcript abundance data. Useful for investigating gene utilization to understand disease or biological processes.
  • Proteomics. For spectral data on peptides or metabolites. Useful for identifying protein biomarkers and their association with disease or traits.